Whitehawk Therapeutics (WHWK) Consolidated Net Income (2018 - 2025)
Historic Consolidated Net Income for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.7 million.
- Whitehawk Therapeutics' Consolidated Net Income fell 4106.02% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 6725.19%. This contributed to the annual value of -$63.7 million for FY2024, which is 315.37% up from last year.
- Whitehawk Therapeutics' Consolidated Net Income amounted to -$17.7 million in Q3 2025, which was down 4106.02% from -$52.8 million recorded in Q2 2025.
- In the past 5 years, Whitehawk Therapeutics' Consolidated Net Income ranged from a high of -$1.5 million in Q2 2021 and a low of -$87.1 million during Q3 2021
- Over the past 5 years, Whitehawk Therapeutics' median Consolidated Net Income value was -$16.0 million (recorded in 2021), while the average stood at -$20.3 million.
- In the last 5 years, Whitehawk Therapeutics' Consolidated Net Income tumbled by 291134.16% in 2021 and then skyrocketed by 8338.0% in 2022.
- Whitehawk Therapeutics' Consolidated Net Income (Quarter) stood at -$16.0 million in 2021, then grew by 12.99% to -$13.9 million in 2022, then dropped by 16.93% to -$16.3 million in 2023, then dropped by 12.32% to -$18.3 million in 2024, then grew by 3.16% to -$17.7 million in 2025.
- Its Consolidated Net Income stands at -$17.7 million for Q3 2025, versus -$52.8 million for Q2 2025 and -$14.4 million for Q1 2025.